Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to 0.93.

  • Agios Pharmaceuticals' Equity Ratio rose 209.25% to 0.93 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.93, marking a year-over-year increase of 209.25%. This contributed to the annual value of 0.93 for FY2024, which is 705.56% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Equity Ratio stood at 0.93 for Q3 2025, which was up 209.25% from 0.93 recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Equity Ratio high stood at 0.94 for Q1 2025, and its period low was 0.85 during Q2 2024.
  • Over the past 5 years, Agios Pharmaceuticals' median Equity Ratio value was 0.9 (recorded in 2023), while the average stood at 0.9.
  • Per our database at Business Quant, Agios Pharmaceuticals' Equity Ratio surged by 9185.93% in 2021 and then tumbled by 384.49% in 2024.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Equity Ratio stood at 0.9 in 2021, then decreased by 1.11% to 0.89 in 2022, then fell by 2.61% to 0.87 in 2023, then increased by 7.06% to 0.93 in 2024, then grew by 0.04% to 0.93 in 2025.
  • Its Equity Ratio was 0.93 in Q3 2025, compared to 0.93 in Q2 2025 and 0.94 in Q1 2025.